All In Biotech

Drug Trial Radar · NCT06231381

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

A Phase II, Multicenter, Double-blind, Randomized, Placebo Parallel-controlled Trial to Evaluate the Efficacy and Safety of HB0034 in Patients with GPP Presenting with an Acute Flare of Moderate to Severe Intensity

Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Feb 29, 2024

Primary completion

Feb 13, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

Conditions

  • Generalized Pustular Psoriasis (GPP)

Interventions

  • HB0034Drug

    Anti-IL-36R antibody

  • PlaceboOther

    non-biologically active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieved GPPGA pustulation subscore of 0/1 (no/almost no visiable pustules) at Week 1.Time frame: Week 1

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital (PKUPH)

    Beijing, China · Recruiting

  • Shanghai Huaota Biopharmaceutical Co., Ltd

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.